Vemurafenib and rituximab in patients with hairy cell leukemia previously treated with moxetumomab pasudotox

Tadeusz Robak¹,², Agnieszka Janus², Krzysztof Jamroziak³, Enrico Tiacci⁴*, Robert J. Kreitman⁵*

¹Department of Hematology, Medical University of Lodz, Lodz, Poland, ²Copernicus Memorial Hospital, Lodz, Poland, ³Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ⁴Hematology, University and Hospital of Perugia, Perugia, Italy, ⁵Clinical Immunotherapy Section, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD, 20892, USA.

*These authors contributed equally.

Short title: Hairy cell leukemia

Correspondence:

Tadeusz Robak

Department of Hematology

Medical University of Lodz

Copernicus Memorial Hospital, 93-510 Lodz

Ul. Ciolkowskiego 2, Poland

e-mail: robaktad@csk.umed.lodz.pl

tel: +48 42 689-51-91

fax: +48 42 689-51-92

Orcid  http://orcid.org/0000-0002-3411-6357

Key words: BRAF, cladribine, dabrafenib, hairy cell leukemia, moxetumomab pasudotox, rituximab, vemurafenib,
Abstract The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80 to 90%. However, HCL patients continue to relapse, and sooner or later, most require subsequent lines of treatment. This report presents the relapsed patients with classic HCL who were treated with vemurafenib (mostly at the low dose of 240 mg twice daily for 16 weeks) combined with rituximab after the failure of several lines of therapy including cladribine with or without rituximab and moxetumomab pasudotox. Two patients achieved CR MRD (-) after combined treatment with vemurafenib and rituximab, with a hematologic response ongoing after 38 months from the end of treatment in one patient and a relapse of cytopenias occurring after 13 months in the other patient. A third patient normalized her blood counts and this hematologic response, which was not evaluated in the bone marrow at the end of treatment, was lost after 18 months. The last patient died due to infection and multi-organ failure, too early to verify response to vemurafenib. Two patients who had relapsed after vemurafenib and rituximab derived meaningful clinical benefit from retreatment with the same agents, but eventually relapsed again and started indefinite therapy with dabrafenib and trametinib with normalization of the blood counts despite heavy bone marrow infiltration in the only patient so far evaluable. The outcomes of these cases indicate that novel targeted agents, and in particular vemurafenib combined with rituximab, improve the prognosis of HCL patients, even those heavily pretreated with PNAs and moxetumomab pasudotox.

1. Introduction

Hairy cell leukemia (HCL) is a rare chronic B-cell neoplasm originating from a mature B lymphocyte; it is characterized by marked splenomegaly, progressive pancytopenia, and infiltrations of the bone marrow (BM) with reactive marrow fibrosis [1,2]. The annual incidence of HCL is estimated to be 0.3 cases per 100,000 and the disease constitutes 2-3% of all leukemias [3,4]. A diagnosis of HCL is established by a combination of peripheral blood smear, flow cytometry and bone marrow biopsy. Recently, it has been found that the BRAF p.V600E somatic mutation is present in 90% to 100% of patients with classic HCL, and this has been described as a disease-defining genetic event [5]. The drugs of choice in the treatment of HCL are purine nucleoside analogs (PNAs), cladribine (2-CdA) and pentostatin (DCF) [1,2]. These agents induce durable complete response (CR) in more than 70% of first line patients, and are also effective in re-induction therapy. However, the patients continue to relapse, with median response duration of 8–10 years, and most experience several relapses [6,7]. Repeated treatments with the same PNA are effective in some patients, but the CR rate
and response duration following subsequent courses typically shorten with subsequent treatments [7-9]. Patients who relapse within two or three years after the first PNA treatment have worse prognosis and lower likelihood of the second durable CR achievement. In addition, in some cases, the disease is refractory to PNA therapy. The median duration of response to second line 2-CdA monotherapy is 2-9 years [8,9].

Moxetumomab pasudotox (Moxe, LUMOXITI™), is a recombinant immunotoxin composed of the Fv fragment of an anti-CD22 monoclonal antibody fused to a 38-kDa fragment of Pseudomonas exotoxin (PE38) [10]. Its approval was based on phase 1 and phase 3 clinical trials evaluating the safety and efficacy of the drug in relapsed/refractory HCL [10-12]. The BRAF V600E mutation inhibitors vemurafenib and dabrafenib also exhibit remarkable activity in multiply-relapsed and refractory patients with classic HCL [13-15, 24]. Combining BRAF inhibitors with anti-CD20 monoclonal antibodies or MEK inhibitor as therapy can be even more effective than using the BRAF inhibitors alone [16-17].

However, the optimal drug sequencing for relapsed/refractory HCL remains unestablished. The present study reviews data from four heavily-pretreated HCL patients who received combination therapy of vemurafenib and rituximab after the failure of Moxe.

2. Materials and methods

This retrospective study examines the cases of four patients with classic HCL who were treated with vemurafenib and rituximab following relapse after Moxe. Their clinical records were identified in the hospital registry at Copernicus Memorial Hospital (Lodz, Poland). All patients were found to be positive for BRAF p.V600E, as indicated by the AS PCR test for the BRAF V600E mutation; this has an analytical sensitivity 0.1% mutated allele [18]. AE were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Common Terminology Criteria for Adverse Events (CTCAE). Version 5 Ed, National Cancer Institute, 2017. Response to therapy was evaluated using the consensus guidelines for the diagnosis and management of patients with HCL [1]. The investigation was carried out following the rules of the Declaration of Helsinki of 1975, revised in 2013. The study was approved on May 19, 2015 by the Clinical Research Ethics Committee from the Medical University of Lodz (No RNN/145/15 /KE) and by the Pharmacotherapy Committee from Copernicus Memorial Hospital, Lodz, Poland on July 16, 2020.

3. Results
The demographics, prior treatments and clinical outcomes of the four patients are summarized in Table 1. Before Moxe initiation, all patients had been previously treated with at least three regimens and one patient with six lines of therapy. Previous treatments included 2-CdA monotherapy, 2-CdA combined with rituximab, and IFN-α. The median time from diagnosis to Moxe initiation was 112 (range 28-258) months. All four patients were treated with Moxe at 40 micrograms QOD x3 for five-six courses within a phase 3 clinical trial. Two patients achieved a CR and two PR, with hematologic remission lasting 11 to 38 months from the end of treatment (Table 1). None of the four patients experienced serious adverse reactions, such as capillary leak syndrome or hemolytic uremic syndrome. In all four patients, vemurafenib plus rituximab was given as the subsequent treatment after Moxe due to HCL progression, with no serious adverse reactions from this combo regimen. One patient (No 4), who started vemurafenib at the dose of 960 mg BID, was not evaluable as he died early of a severe infection (after having survived for 302 months from HCL diagnosis). In the other three patients, the drug was given at the low dose of 240 mg BID for 16 weeks in combination with rituximab (375mg/m²/d/iv) every two weeks for eight doses. Two patients achieved MRD negative CR with hematologic remission that was ongoing at 38 months from the end of treatment in one case, while it was lost after 13 months in the other case. The third patient achieved a hematologic remission (with unknown bone marrow response at the end of treatment), that was lost after 18 months. The two patients who progressed after vemurafenib plus rituximab were successfully retreated with this regimen and derived clinical benefit for a duration that was similar (in one patient) and lower (in the other patient) compared to the previous course. At eventual relapse, both patients were started on indefinite dabrafenib and trametinib; one of these two patients (no 3) has regained a hematologic remission since 8 months despite persistence of marked leukemic infiltration of the bone marrow, while the other patient (no 2) has just started treatment and is not evaluable.

Case description

Case 1. A 28-year old woman with pancytopenia, symptoms of hemorrhagic diathesis and splenomegaly (160mm) was first seen in July 2008. Complete blood count (CBC) at admission showed Hb 10.2g/dl, WBC 3.7×10³/µl, ANC 0.6×10³/µl, PLT 49×10³/µl and 60% HCL infiltration in BM biopsy. A diagnosis of HCL was confirmed by immunohistochemistry and flow cytometry. In August 2008 she received first-line treatment with 0.12mg/kg/d/i.v. 2-CdA and obtained a partial response (PR) with 5% HCL cells in BM biopsy. She relapsed in
April 2010 with progressive pancytopenia and 50% HCL infiltration in bone marrow (BM). Second-line treatment was administered, consisting of 0.12mg/kg/d/iv/ 2-CdA for five days, followed 4 months later by four doses of rituximab (375mg/m²/iv, once per week). In September 2010, a partial response (PR) was confirmed with 8% of HCL infiltration in BM.

The second relapse was noted in February 2011 with pancytopenia and 20% of HCL cells in BM biopsy. She started interferon alpha (IFN-α) at a dose of 3 mln IU, 3x per week given for five months, and obtained only a PR lasting until June 2012 when pancytopenia returned with 50% of HCL infiltration in BM biopsy. In September 2012, treatment with 0.12mg/kg/d 2-CdA was applied for five days, and again a PR was achieved with 5% HCL cells in BM.

The fourth relapse was confirmed in October 2014 with pancytopenia and 60% of HCL cell infiltration in BM biopsy. In April 2015, the fifth-line treatment was begun, with six cycles of Moxe (40 micrograms QOD x3), within the phase 3 clinical trial at the NIH Clinical Center. In October 2015 she demonstrated CBC resolution and resolution of splenomegaly with significant reduction of HCL infiltration in the BM biopsy (from 80% of hairy cell involvement before treatment to 20-30% two months after therapy). At the end of the treatment, she fulfilled the criteria for PR. In August 2017, she experienced the fifth disease relapse, with Hb 12.3 g/dl, WBC 2.32x10³ /µl, ANC 0.83x10³/µl and PLT 73x10³/µl. The relapse was confirmed by a BM performed in August 2017, indicating 70% infiltration by HCL cells. Moreover, the presence of BRAF p.V600E mutation was confirmed by AS-PCR in the PB and BM aspirate. In September 2017, she started treatment with vemurafenib (240 mg BID for 4 months) in combination with rituximab (375mg/m²/iv) every two weeks for eight doses. During the treatment, she complained of diffuse arthralgia and skin rash. In response to these symptoms, concomitant treatment with prednisone 10 mg/d/orally was initiated, with success. CBC recovery was observed after one month of treatment. After the end of the therapy in January 2018 she obtained a MRD negative complete response (CR) confirmed by an assessment of the BM aspirate and flow cytometry, BM trephine biopsy and AS-PCR for BRAF p.V600E mutation in the peripheral blood (PB) and BM aspirate (with a sensitivity threshold of 0.1% mutant alleles). As of April 2021, 38 months after treatment discontinuation, the patient has remained without any evidence of the disease with Hb 13.7 g/dl, WBC 4.35x10³ /µl, ANC 2.43x10³/µl and PLT 176x10³/µl.

**Case 2**

A 33-year old woman was diagnosed with symptomatic HCL in June 2013. Physical examination revealed splenomegaly, while CBC at this time showed Hb 8.4 g/dl, WBC
1.75×10^3/µl, ANC 0.31×10^3/µl, PLT 59×10^3/µl. BM biopsy found 80% of HCL cells to be CD19+, CD20+ CD22+, CD11c+, CD25+ and CD103+. Between June and August 2013 she received first-line treatment with 2-CdA dosed 0.12mg/kg/d/i.v./d x 6 in a weekly schedule; however, only a PR was achieved, with 20% of HCL infiltration (November 2013). In January 2014, she received an additional course of 2-CdA (7mg/day for five consecutive days), which also resulted in a PR. Subsequently, the patient relapsed in September 2014, with pancytopenia and 80% HCL infiltration in BM biopsy. Second-line treatment with IFN-α 3 mln U x 3 per week was administered from September 2014 to December 2014 without response. The disease progressed in January 2015 and she began third-line treatment with 2-CdA in combination with eight doses of rituximab (375mg/m^2/d/iv), one dose every other week. A PR was obtained, which lasted only six months. In September 2015, she started Moxe 40µg/kg i.v. on days 1, 3 and 5 of each 28 day cycle for six courses within a pivotal multicenter, open-label, single-arm trial[11,12]. Treatment was completed in March 2016. No adverse events (AE) were observed and again PR was achieved. In November 2016 she experienced the fourth relapse, with progressive pancytopenia including transfusion–dependent anemia and infections. CBC at this time revealed WBC 1.46×10^3/µl, ANC0.45×10^3/µl, RBC 2.92 ×10^6/µl, Hb 9.5 g/dl, HCT 28.6%, PLT 107×10^3/µl. The BM biopsy confirmed 75% hairy cell involvement, and the AS-PCR test confirmed the presence of BRAF p.V600E somatic mutation. In January 2017 she started the fifth-line treatment with vemurafenib 960 mg BID and rituximab 375mg/m^2/d/iv scheduled every two weeks for eight doses. After the initial two weeks, the dose of vemurafenib was reduced to 240 mg BID due to intolerance (photosensivity, arthralgia, musculoskeletal pain, rash); treatment was continued for a further 16 weeks without any further complications. Cytopenias resolved after one month from the start of treatment. The bone marrow evaluation, which was not performed after the end of treatment in April 2017 but 9 months later in January 2018, showed substantial leukemic infiltration (60-70% of the marrow cellularity). In January 2019, she was admitted to the emergency room because of fever and fatigue. Her CBC revealed WBC 0.91 x10^3/µl, ANC 0.54 x10^3/µl, Hb 8.1 g/dl and PLT 135 x10^3/µl. Bone marrow aspirate and trephine biopsy confirmed the relapse of HCL. In February 2019, re-treatment with 240 mg BID vemurafenib for 16 weeks with eight doses of 375mg/m^2/d/iv rituximab (one dose every two weeks) was initiated. To prevent previous noted vemurafenib toxicities, 10 mg prednisone was initiated. PB counts normalized four weeks after re-treatment initiation, and a CR MRD (+) was documented in a bone marrow evaluation done in October 2019 about 4 months after the end of treatment, with the BRAF p.V600E mutation present at an allele
frequency of 0.085%. She remained in remission for 17 months. In February 2020, progression of HCL was diagnosed with pancytopenia (WBC 1.80 x10^3/µl, ANC 0.5 x10^3/µl, Hb 8.3g/dl, PLT 146 x10^3/µl) and 80% of hairy cell involvement in BM trephine biopsy. In April 2021 she started combined therapy with dabrafenib (Tafinlar) 75-150 mg/d BID p.o. and trametinib (Mekinist) 2mg/day and currently she has been maintained on these drugs for four weeks.

**Case 3**

A 53-year-old man was first seen in our Department in July 2003 because of fever and pancytopenia. On admission, his CBC revealed WBC 1.46x10^3/µl, ANC 0.45 x10^3/µl, Hb 8.5 g/dl, PLT 75 x10^3/µl and moderate splenomegaly (130 mm). Bone marrow biopsy confirmed a diagnosis of classic HCL by immunohistochemistry and flow cytometry. The first course of 0.12mg/kg/d/i.v. 2-CdA was administered for five days in July 2003, and a CR was obtained. After a relapse, a second course of 2-CdA at the same dose was administered in January 2005 and a CR was again achieved. Following a second relapse, a third course of 0.12mg/kg/d/i.v. 2-CdA was given for seven days in April 2007 which resulted in a CR. Progression was reported in 2015 and in December 2015, he started Moxe as a part of a phase 3 clinical trial. After five courses, the treatment was ended because of kidney failure. The patient obtained a MRD negative CR; this was confirmed by HCL-negative trephine biopsy and the absence of HCL cells in a flow cytometry analysis of PB and BM, performed in November 2016, six months after last course of Moxe. In October 2017, he was admitted to our hospital because of anemia, thrombocytopenia and infection. CBC on admission revealed WBC 5.6x10^3/µl, ANC 1.67 x10^3/µl, Hb 8.2 g/dl and PLT 24x10^3/µl. BM aspirate was consistent with 60% infiltration with HCL cells, and the presence of BRAF V600E mutation was confirmed by PCR. Between November and February 2018, the patient was treated with vemurafenib (240 mg BID) and 375mg/m^2/d/iv rituximab every 2 weeks for eight doses. Blood counts normalized within 1 month. There were not observed any toxicities. MRD-negative CR was obtained after the end of treatment, as confirmed by the BM aspirate, BM flow cytometry, trephine biopsy and AS-PCR for BRAF p.V600E mutation in the PB and BM (sensitivity: 0.1% mutant alleles). However, the patient relapsed in February 2019, with massive splenomegaly (320x120mm) and pancytopenia. In March 2019 retreatment was started with vemurafenib at the dose 240 mg BID for 7 weeks in combination with rituximab 375mg/m2/i.v. for a total of 4 doses administered every two weeks. After one month blood counts improved without however any reduction of splenomegaly. The patient was
splenectomized in May 2019. As a result of this salvage therapy, short-termed hematological remission was obtained. In September 2019 the disease recurred with pancytopenia and gastrointestinal tract bleeding as a result of severe thrombocytopenia. In October 2019, retreatment with vemurafenib (240mg BID), and rituximab (eight doses, one every other week) was started and continued for 16 weeks until February 2020, without any toxicities. Following treatment, the CBC returned to normal at the end of the treatment (WBC 9.45×10^3/µl, ANC 6.64 ×10^3/µl, Hb 12.4 g/dl, and PLT 278 ×10^3/µl); a bone marrow biopsy was not performed. He relapsed again in June 2020 (WBC 6.15 ×10^3/µl /µl, ANC 3.36 ×10^3/µl, Hb 8.7 g/dl and PLT 16 ×10^3/µl); BM biopsy showed 85% infiltration by HCL cells. In July 2020, combined treatment with dabrafenib (150 mg BID p.o.) and trametinib (2 mg/day) was initiated. Two weeks later, the dose of both drugs was reduced (dabrafenib 75 mg BID, and trametinib 2 mg every other day) due to progressive pancytopenia (WBC 2.5 ×10^3/µl, ANC 0.82 ×10^3/µl, Hb 8.7 g/dl, PLT 39 ×10^3/µl). Hematologic remission was first achieved 2 months after starting treatment and was maintained until April 2021, when he developed mild thrombocytopenia (PLT 112x10^3/µl ) and trephine biopsy showed 80% leukemic infiltration.

Case 4

A 45-year-old man was first seen with pancytopenia and splenomegaly in June 1994. A BM biopsy was consistent with diagnosis of classic HCL by immunohistochemistry and flow cytometry. In October 1994, treatment was initiated with 0.12mg/kg/d/i.v. 2-CdA for five days, resulting in a PR (Table 1). The patient relapsed in August 1995 and again received the second-line treatment with 0.12mg/kg/d/i.v. 2-CdA for five days. A PR was achieved, which lasted until November 1997. In January 1998, the third-line treatment with 2-CdA was implemented and the patient achieved a CR. A third progression was noted in January 2010, and in February 2010 the patient was treated with a fourth five-day course of 2-CdA, achieving a PR. Two years later (January 2012), a fourth progression was observed. He was treated with the fifth course of 2-CdA and again a PR was achieved, which lasted until April 2013. In May 2013, the patient was treated with one course of 2-CdA 0.12mg/kg/d/i.v. for five days; combined with four doses of rituximab, however, only PR was achieved. He relapsed in November 2015, and in January 2016, the patient was included into the clinical trial with Moxe (40µg/kg i.v. on days 1, 3 and 5 of each 28-day cycle for six cycles). Following this sixth course of treatment, BM biopsy revealed CR MRD negative and no AEs were observed. In August 2019, he was admitted to our Department with progressive
pancytopenia (WBC 1.15x10^3/µl, ANC 0.15x10^3/µl, Hb 10.2g/dl, PLT 14x10^3/µl). BM biopsy confirmed progression of HCL with 90% marrow involvement, and the BRAF p.V600E mutation was detected. Salvage treatment was initiated with vemurafenib 960 mg orally twice a day and one dose of rituximab (375mg/m^2/d/iv), simultaneously with filgrastim. Considering the profound decline in ANC, rituximab was withheld. However, three weeks later, the patient developed pneumonia and septic shock with blood cultures positive for multi-resistant *Pseudomonas aeruginosa* and died of multi-organ failure.

4. Discussion

Conventional treatment with PNAs has been shown to provide a long-lasting hematological and clinical response in most patients with classic HCL. However, the patients often relapse and require multiple treatments, and may thus become refractory to re-treatment with PNAs. Fortunately, the recent introduction of novel agents has expanded the spectrum of therapy possibilities for those patients, and now, treatment options for the management of early-relapsed patients, or those refractory to PNAs, include IFN-α, rituximab and Moxe [19].

We reviewed the records from four patients treated at Copernicus Memorial Hospital, Lodz, Poland; all received multiple lines of 2-CDA and were subsequently treated with Moxe, followed by vemurafenib combined with rituximab. In addition, two patients were treated with IFN-α after relapse with 2-CdA: one of them did not respond and one obtained only a PR lasting 17 months. IFN-α may still have a place in the treatment, but its use is currently limited, being restricted to pregnant patients and in patients presenting with neutropenia below 0.2×10^9/L, when the risk of infection is high [20,21]. Our patients received Moxe within the pivotal, phase 3 multicenter study [11, 12]. All patients responded to the treatment, two with PR and two with CR, with hematologic remission lasting from 11 to 38 months after the end of treatment. These results are in agreement with those of a previous phase 1 and phase 3 trial, which included similar patient populations (with a median of 3 prior therapies): these trials demonstrated a durable CR of 30 to 64 percent, and an objective response rate (ORR) of 75 to 88 percent of the patients [10,22]. In addition, 82 to 85 percent of complete responders achieved MRD negativity [12, 22]. Moxe has been approved by FDA for the treatment of patients with relapsed or refractory HCL after previous treatment with at least two lines of therapy, including at least one PNA [23]. Moxe is now being tested in combination with rituximab to improve/hasten response and prevent immunogenicity, and the Moxe-rituximab combination may prove to be better than the single agent.
More recently, vemurafenib, dabrafenib, trametinib and ibrutinib are currently under investigation in patients unsuitable for PNAs [13, 24-29]. These agents have been proposed as relatively safe drugs, even in pretreated patients, with severe neutropenia and (in the case of BRAF inhibitors) infections. However, they are still considered “off-label” in the treatment of this disease.

In particular, the BRAF inhibitor vemurafenib was evaluated in relapsed and refractory patients with classic HCL in two phase 2 multicenter studies [13]. The drug was administered at a dose of 960 mg, twice daily for a median of 16-18 weeks. The OR rates were 96% to 100% with CR rates of 35% to 42%, and responses were obtained after a median of 8 to 12 weeks. Interestingly, while vemurafenib had been originally suggested to have similar effectiveness when used at much lower doses in a retrospective case series[14], an update of the same series expanded with additional patients showed that doses of vemurafenib lower than 480 mg bid might have suboptimal efficacy [15]. In particular, patients who received high-dose BRAFi treatment (vemurafenib ≥ 480 mg bid, dabrafenib ≥ 150 mg bid) demonstrated significantly longer treatment-free survival (median, 14.6 months) than patients who were treated with lower doses (median, 9.4 months).

In a recently published phase-2 trial on 30 HCL patients with a median of 3 prior therapies (not including Moxe; [17]), adding rituximab (8 doses, one every other week) concomitantly and subsequently to a short treatment with vemurafenib at the dose of 960 mg bid for a total of 8 weeks produced a very high rate of complete remissions (87%) and negativity for minimal residual disease/MRD (60%). These deep responses translated into a durable relapse-free survival of 85% at almost 3 years of follow-up from the end of treatment. Relative dose intensity of vemurafenib was high (median of 92%), attesting to the safety and tolerability of the 960 mg bid dose when given for a short period (8 weeks in total). Receipt of a relative dose intensity <60% seemed to be associated with treatment failure, with the caveat of the low number of these events [17].

This is the first report documenting the activity of vemurafenib plus rituximab even in the context of relapse after Moxe, including hematologic remission in all 3 evaluable patients and MRD-negative CR in the 2 patients who underwent bone marrow evaluation at the end of treatment. Relapse-free survival after the end of treatment was substantial in one case (response ongoing at 38 months, versus 22 months after previous Moxe), while it was lower but still clinically meaningful in the other two cases (18 and 13 months, comparing well with
11 and 17 months after previous Moxe, respectively). When contrasted to the clinical trial of vemurafenib plus rituximab [17], the relapse-free survival in 2 of these 3 patients may appear somewhat lower, which might be due to a higher intrinsic drug resistance of their disease relapsing even after Moxe and/or (as suggested by [15]) to a lower efficacy of the vemurafenib dose used (240 mg bid).

The fourth patient, who had received 7 lines of therapy over 15 years, was not evaluable as he died too early (3 weeks after starting vemurafenib plus rituximab) of a severe infection caused by a pre-existing deep neutropenia, which even such a high effective treatment was not expected to necessarily resolve earlier (indeed, the median time to resolution of neutropenia after vemurafenib plus rituximab is 4 weeks [17]). Nevertheless, previous reports based on small numbers of cases suggested that vemurafenib is a safe and effective drug even in patients with HCL presenting with severe neutropenia, fever and infection [26,27,30].

This report also starts to address the issue of relapse after vemurafenib plus rituximab. Re-treatment with vemurafenib is an option that should be considered in this context, as exemplified by two of our cases enjoying clinical benefit from retreatment, although for a shorter duration in one case. Likewise, Liebers et al report rapid hematologic improvement in 17 patients retreated with BRAF inhibitors (85% previously treated with vemurafenib or dabrafenib) with at least one further BRAFi course [15]; however, the subsequent BRAF inhibitor courses yielded shorter response durations than the initial treatment. Dabrafenib is another BRAF inhibitor that can be used in patients with heavily-pretreated recurrent/refractory BRAF V600E-mutated HCL, including cases previously treated with vemurafenib [24]. Dabrafenib can be also combined with the MEK inhibitor trametinib. Kreitman et al. found combination therapy of indefinite duration (median of 17 months) based on dabrafenib (150 mg twice daily) with the MEK inhibitor trametinib (2 mg once daily) is effective and well tolerated in 43 relapsed/refractory HCL patients with presence of a BRAF V600E mutation [16] who were not previously treated with a BRAF inhibitor. The OR rate was 78% including 49% CRs; Grade 3/4 AEs were observed in 49% of patients. Interestingly, one of our two patients who relapsed after retreatment with vemurafenib plus rituximab has regained a hematologic remission with dabrafenib plus trametinib, while the other has just recently started such therapy and is not well evaluable in this regard.

5. Conclusion
In the coming years, targeted drugs will play a key role in standard therapy for patients with relapsed or refractory HCL after treatment with PNAs. The history of the presented cases indicates that novel targeted agents, and in particular vemurafenib plus rituximab, improve the prognosis of HCL patients, even those who are heavily pretreated with PNAs and Moxe. Still, HCL remains an incurable disease in such an advanced relapsed/refractory disease setting, and the development of novel therapeutic strategies is required.

**Author Contribution:** T.R., A.J., K.J. and R.J.K. provided patient care; E.T. performed \(BRAF\) p.V600E testing with AS PCR. T.R., A.J., K.J., E.T. and R.J.K collected and analyzed the results, wrote and reviewed the paper.

**Funding:** The study was supported in part by grants from the Medical University of Lodz, Poland: No. 503/1-093-01/503-11-004-18.

**Institutional Review Board Statement:** This study was approved by the Clinical Research Ethics Committee from the Medical University of Lodz (No RNN/145/15 /KE) and the institutional review board at the Copernicus Memorial Hospital, Lodz, Poland.

**Informed Consent Statement:** Informed consent was obtained from the patients included in the study.

**Data Availability Statement:** The data presented in this study are available from the corresponding author for request

**Conflicts of Interest:** Conflict-of-interest disclosure: RJK is coinventor on the NIH patent for Moxetumomab Pasudotox. TR and AJ received research grants from Medimmune and Astra Zeneca; KJ and ET declare that they have no conflicts of interest.

**Acknowledgments**

We thank Edward Lowczowski from the Medical University of Lodz for editorial assistance. We are grateful to the patients, medical, nursing, and laboratory staff of the participating departments for their contributions to this study.

**References.**


<table>
<thead>
<tr>
<th></th>
<th>Age at diagnosis /Sex</th>
<th>Therapies before Moxe treatment (response; duration of hematologic response in months/m from the end of treatment)</th>
<th>Moxe treatment (response; duration of hematologic response in months/m from the end of treatment)</th>
<th>Vemurafenib + R treatment</th>
<th>Response to V + R treatment (duration of hematologic response in months/m from the end of treatment)</th>
<th>Subsequent treatment (response; duration of hematologic response in months/m from the end of treatment)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>28/F</td>
<td>1. 2-CdA (PR; 21m); 2. 2-CdA + R (PR; 6 m); 3. IFN-α (PR; 17 m); 4. 2-CdA (PR; 26 m)</td>
<td>40µg/kg IV x 3 every 28 days x 6 (PR; 22 m)</td>
<td>V 240 mg BID for 16 weeks + R 375mg/m²/d/iv/ every 2 weeks x 8</td>
<td>MRD negative CR. (ongoing at 38 m)</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>33/F</td>
<td>1. 2-CdA x 2 courses (PR; 15 m); 2. IFN-α (NR); 3. 2-CdA + R (PR; 6 m)</td>
<td>40µg/kg IV x 3 every 28 days x 6 (PR; 11 m)</td>
<td>V 960mg BID for 2 weeks, (intolerance), dose reduction to 240mg BID for 14 weeks + R 375mg/m²/d/iv/ every 2 weeks x 8</td>
<td>Hematologic response (bone marrow evaluation not performed; 18 m)</td>
<td>V 240mg BID for 16 weeks + R 375mg/m²/d/iv/ every 2 weeks x 8 (MRD positive CR; 17 m).</td>
</tr>
<tr>
<td>3</td>
<td>53/M</td>
<td>1. 2-CdA (CR; 18m); 2. 2-CdA (CR; 27 m); 3. 2-CdA (CR; 98 m);</td>
<td>40µg/kg IV x 3 every 28 d x 6 (CR MRD-; 17 m)</td>
<td>V 240 mg BID for 16 weeks + R 375mg/m²/d/iv/ every 2 weeks x 8</td>
<td>MRD- CR. (13 m)</td>
<td>V 240 mg BID for 7 weeks + R 375mg/m²/d/iv/ every 2 weeks for 4 doses; Splenectomy (PR; 5m)</td>
</tr>
<tr>
<td>No.</td>
<td>Age</td>
<td>Gender</td>
<td>Dose and Treatment</td>
<td>Response</td>
<td>Status</td>
<td>Notes</td>
</tr>
<tr>
<td>-----</td>
<td>-----</td>
<td>--------</td>
<td>--------------------</td>
<td>----------</td>
<td>--------</td>
<td>-------</td>
</tr>
<tr>
<td>4</td>
<td>45</td>
<td>M</td>
<td>1. 2-CdA (PR; 22m); 2. 2-CdA (PR; 27 m); 3. 2-CdA (CR; 144 m); 4. 2-CdA (PR 23 m); 5. 2-CdA (PR 16 m); 6. 2-CdA + R (PR 24 m)</td>
<td>40µg/kg IV x 3 every 28 d x 6 (CR MRD+; 38 m)</td>
<td>V 960mg BID for three weeks, Only 1 dose of R due to infection</td>
<td>Not evaluable</td>
</tr>
</tbody>
</table>

Abbreviations: 2-CdA – 2-chlorodeoxyadenosine, cladribine; CR – complete response; F – female; IFN-α – interferon alpha; PR – partial response; m – months; M – male; Moxe – moxetumomab pasudotox; MRD – minimal residual disease NR – no response; R – rituximab; V - vemurafenib